Plasma pharmacokinetic and metabolism of [18F]THK-5317 are dependent on sex. QPS Plasma pharmacokinetic and metabolism of [18F]THK-5317 are dependent on sex. Read More »
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice. QPS Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice. Read More »
Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease. QPS Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease. Read More »
Correction: Further investigation of phenotypes and confounding factors of progressive ratio performance and feeding behavior in the BACHD rat model of Huntington disease. QPS Correction: Further investigation of phenotypes and confounding factors of progressive ratio performance and feeding behavior in the BACHD rat model of Huntington disease. Read More »
Hepatic and neuronal phenotype of NPC1−/− mice QPS Hepatic and neuronal phenotype of NPC1−/− mice Read More »
Development of GMP-1 a molecular chaperone network modulator protecting mitochondrial function and its assessment in fly and mice models of Alzheimer’s disease. QPS Development of GMP-1 a molecular chaperone network modulator protecting mitochondrial function and its assessment in fly and mice models of Alzheimer’s disease. Read More »
BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains. QPS BACE1-cleavage of Sez6 and Sez6L is elevated in Niemann-Pick type C disease mouse brains. Read More »
Phosphorylation of different tau sites during progression of Alzheimer’s disease. QPS Phosphorylation of different tau sites during progression of Alzheimer’s disease. Read More »
mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms. QPS mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms. Read More »
Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease. QPS Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s Disease. Read More »
SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer’s disease. QPS SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer’s disease. Read More »
Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. QPS Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form. Read More »